CSF2 and neoplasm: Currently, the only FDA-approved OV is talimogene laherparepvec (T-VEC), an intralesional injection of a modified herpes virus that leads to tumor lysis and granulocyte macrophage colony-stimulating factor (GM-CSF) delivery.